GE HealthCare Techsの空売り状況は、投資家がGE HealthCare Techsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

GE HealthCare Techs (NASDAQ:GEHC) 株価情報, 空売り情報

GE HealthCare Techs

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Technologies Inc

GE HEALTHCARE TECHNOLOGIES ORD

WIIM

PACB

Pacific Biosciences shares are trading lower after the company reported worse-than-expected Q3 revenue results.

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) sees Q4 sales of $76.000 million-80.000 million vs $79.31 million estimate.

News

Guidance

MLNK

MeridianLink Sees Q4 Sales $76.000M-80.000M vs $79.31M Est

Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) reported quarterly losses of $(1.51) per share which beat the analyst consensus estimate of $(2.02) by 25.25 percent. This is a 54.1 percent increase over losses of $(3.29) per share from the same period last year. The company reported quarterly sales of $6.84 million which missed the analyst consensus estimate of $8.64 million by 20.78 percent.

Earnings

Earnings Beats

Earnings Misses

ASMB

Assembly Biosciences Q3 EPS $(1.51) Beats $(2.02) Estimate, Sales $6.84M Miss $8.64M Estimate

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) narrows FY2024 sales outlook from $312.00 million-318.00 million to $313.00 million-317.00 million.

MeridianLink Narrows FY2024 Sales Guidance to $313.00M-317.00M  VS Est.315.81M

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 200 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $126.111 million which beat the analyst consensus estimate of $122.733 million by 2.75 percent. This is a 2.50 percent increase over sales of $123.036 million the same period last year.

BARK

BARK Q2 2025 Adj. EPS $0.01 Beats $0.00 Estimate, Sales $126.111M Beat $122.733M Estimate

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) narrows FY2024 sales outlook from $300.00 million-315.00 million to $305.00 million-310.00 million.

LPSN

LivePerson Narrows FY2024 Sales Guidance from $300.00M-315.00M to $305.00M-310.00M

RDFN

Redfin shares are trading lower after the company reported worse-than-expected Q3 financial results.

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) sees Q4 sales of $65.700 million-70.700 million vs $71.26 million estimate.

LivePerson Sees Q4 Sales $65.700M-70.700M vs $71.26M Est

Offerings

Cousins Properties Announces Public Offering of 6,000,000 Shares of Common Stock

SEZL

Sezzle shares are trading higher after the company reported a year-over-year increase in Q3 financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.25 by 4 percent. The company reported quarterly sales of $1.52 billion which missed the analyst consensus estimate of $1.53 billion by 0.25 percent. This is a 55.26 percent increase over sales of $981.58 million the same period last year.

Stantec Q3 2024 Adj EPS C$1.30 Beats C$1.25 Estimate, Sales C$1.52B Miss C$1.53B Estimate

Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.73) by 10.96 percent. This is a 8.45 percent increase over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $2.34 million which missed the analyst consensus estimate of $4.27 million by 45.29 percent. This is a 17.10 percent decrease over sales of $2.82 million the same period last year.

Avidity Biosciences Q3 EPS $(0.65) Beats $(0.73) Estimate, Sales $2.34M Miss $4.27M Estimate

Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.09 by 33.33 percent. This is a 14.29 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $34.42 million which missed the analyst consensus estimate of $36.31 million by 5.20 percent. This is a 4.21 percent increase over sales of $33.03 million the same period last year.

LTRX

Lantronix Q1 Adj $0.06 Misses $0.09 Estimate, Sales $34.42M Miss $36.31M Estimate

Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) lowers FY2024 sales outlook from $1.20 billion to $1.10 billion.

FOSL

Fossil Group Lowers FY2024 Sales Guidance from $1.20B to $1.10B

Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.75) by 5.33 percent.

RCKT

Rocket Pharmaceuticals Q3 2024 GAAP EPS $(0.71) Beats $(0.75) Estimate

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) affirms FY2024 sales outlook from $225.00 million-235.00 million to $225.00 million-235.00 million.

CYRX

CryoPort Affirms FY2024 Sales Guidance to $225.00M-235.00M  VS Est.229.73M

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 22.22 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $250.885 million which missed the analyst consensus estimate of $252.108 million by 0.49 percent. This is a 4.85 percent increase over sales of $239.287 million the same period last year.

NVEE

NV5 Global Q3 2024 Adj. EPS $0.44 Beats $0.41 Estimate, Sales $250.885M Miss $252.108M Estimate

FRLA

Fortune Rise Acquisition Extends To Complete Business Combination From Nov. 5 To Dec. 5

PRPH

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $213.300 million which beat the analyst consensus estimate of $210.729 million by 1.22 percent. This is a 11.15 percent increase over sales of $191.900 million the same period last year.

MYGN

Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $213.300M Beat $210.729M Estimate

From Spin-Off To Standout: GE HealthCare Is Pretty Impressive

GE Healthcare Technologies Inc (GEHC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst P...

Hold Rating on GE Healthcare Due to Stagnant Demand and Uncertain Growth Prospects

Piper Sandler raised the firm's price target on GE HealthCare (GEHC) to $97 from $95 and keeps an Overweight rating on the shares. The firm notes G...

GE HealthCare price target raised to $97 from $95 at Piper Sandler

Oppenheimer analyst Suraj Kalia maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) today and set a price target of ...

Oppenheimer Reaffirms Their Buy Rating on GE Healthcare Technologies Inc (GEHC)

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) today. The company's shares cl...

Stifel Nicolaus Sticks to Its Buy Rating for GE Healthcare Technologies Inc (GEHC)

Healthcare Investing Finding Growth Beyond Pharmaceuticals

BTIG analyst Ryan Zimmerman maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) yesterday and set a price target of ...

BTIG Sticks to Its Buy Rating for GE Healthcare Technologies Inc (GEHC)

GE HealthCare: Light Up With Growth Indicators In Medical Tech, While Undervalued

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report), with a pri...

Promising Outlook for GE Healthcare: Buy Rating Backed by Innovation, Growth, and Margin Improvements

GE HealthCare (GEHC) Technologies announced the launch of a secondary underwritten public offering of 13.28M shares of its common stock. GE HealthC...

GE HealthCare announces offering of 13.28M shares of common stock for holders

AGNG

ARKG

BMED

CNCR

EDOC

FHLC

FTXH

GEHC

GNOM

HART

HELX

HTEC

IBBQ

IDNA

IDXX

ISRG

LABU

MDEV

PILL

PINK

PSCH

RSPH

SBIO

UTHR

VEEV

WDNA

Press Releases

GE HealthCare Accelerates Artificial Intelligence Adoption With New Offering to Advance Enterprise Imaging

GE HealthCare introduces easy-to-use, easy-to-learn, easy-to-diagnose Versana Premier multi-purpose ultrasound system

A New Theranostics Center of Excellence in Europe: GE HealthCare and University Medicine Essen Collaborate to Advance Theranostics and Personalized Medicine

Comments

GE HealthCare Techs

空売り

GE HealthCare Techs (NASDAQ:GEHC) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル